Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Chi

Showing results (161-170 of 410) with videos related to

Pageof 41
Sort By:
Nature Communications|October 20, 2022
Atomic resolution protein allostery from the multi-state structure of a PDZ domainDzmitry Ashkinadze, Harindranath Kadavath, Aditya Pokharna, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 30, 2016
A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancersK N Chi, E Y Yu, C Jacobs, et al.
European Urology|February 11, 2014
Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance statusArun A Azad, Bernhard J Eigl, Raya Leibowitz-Amit, et al.
Journal of Neuro-Oncology|April 2, 2005
Continuous remission of newly diagnosed and relapsed central nervous system atypical teratoid/rhabdoid tumorMary Ann Zimmerman, Liliana C Goumnerova, Mark Proctor, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 27, 2014
Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal eventsM R Smith, R E Coleman, L Klotz, et al.
Molecular Cancer Therapeutics|September 13, 2022
p53 Pathway Inactivation Drives SMARCB1-deficient p53-wildtype Epithelioid Sarcoma Onset Indicating Therapeutic Vulnerability Through MDM2 InhibitionFelix Oppel, Senyao Shao, Sarah Gendreizig, et al.
International Journal of Cancer|November 5, 2011
Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of diseaseLuke A Selth, Scott Townley, Joanna L Gillis, et al.
Cancer Chemotherapy and Pharmacology|July 4, 2012
Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancerA W Tolcher, K N Chi, N D Shore, et al.
Biorxiv : the Preprint Server for Biology|February 23, 2026
Conformational dynamics at the pre-miR-377 Dicer site governs selective small-molecule recognitionJacopo Manigrasso, Emeline Mestdach, Riccardo Quaia, et al.
Journal of the American Chemical Society|December 2, 2011
Side-chain interactions form late and cooperatively in the binding reaction between disordered peptides and PDZ domainsS Raza Haq, Celestine N Chi, Anders Bach, et al.
Pageof 41

Showing results (161-170 of 410) with videos related to

Sort By:
Pageof 41
Nature Communications|October 20, 2022
Atomic resolution protein allostery from the multi-state structure of a PDZ domainDzmitry Ashkinadze, Harindranath Kadavath, Aditya Pokharna, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 30, 2016
A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancersK N Chi, E Y Yu, C Jacobs, et al.
European Urology|February 11, 2014
Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance statusArun A Azad, Bernhard J Eigl, Raya Leibowitz-Amit, et al.
Journal of Neuro-Oncology|April 2, 2005
Continuous remission of newly diagnosed and relapsed central nervous system atypical teratoid/rhabdoid tumorMary Ann Zimmerman, Liliana C Goumnerova, Mark Proctor, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 27, 2014
Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal eventsM R Smith, R E Coleman, L Klotz, et al.
Molecular Cancer Therapeutics|September 13, 2022
p53 Pathway Inactivation Drives SMARCB1-deficient p53-wildtype Epithelioid Sarcoma Onset Indicating Therapeutic Vulnerability Through MDM2 InhibitionFelix Oppel, Senyao Shao, Sarah Gendreizig, et al.
International Journal of Cancer|November 5, 2011
Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of diseaseLuke A Selth, Scott Townley, Joanna L Gillis, et al.
Cancer Chemotherapy and Pharmacology|July 4, 2012
Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancerA W Tolcher, K N Chi, N D Shore, et al.
Biorxiv : the Preprint Server for Biology|February 23, 2026
Conformational dynamics at the pre-miR-377 Dicer site governs selective small-molecule recognitionJacopo Manigrasso, Emeline Mestdach, Riccardo Quaia, et al.
Journal of the American Chemical Society|December 2, 2011
Side-chain interactions form late and cooperatively in the binding reaction between disordered peptides and PDZ domainsS Raza Haq, Celestine N Chi, Anders Bach, et al.
Pageof 41